Cellectis (CLLS) Earning Somewhat Favorable Press Coverage, Study Finds

Press coverage about Cellectis (NASDAQ:CLLS) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellectis earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.8119212342817 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of Cellectis (NASDAQ CLLS) opened at $29.48 on Friday. The firm has a market capitalization of $1,059.16, a price-to-earnings ratio of -12.23 and a beta of 2.12. Cellectis has a one year low of $17.29 and a one year high of $35.07.

Cellectis (NASDAQ:CLLS) last released its earnings results on Monday, November 13th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.16). Cellectis had a negative net margin of 217.25% and a negative return on equity of 30.66%. sell-side analysts anticipate that Cellectis will post -2.89 EPS for the current year.

Several research firms have recently weighed in on CLLS. Zacks Investment Research lowered Cellectis from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th. Jefferies Group reissued a “buy” rating and set a $47.00 price objective on shares of Cellectis in a research note on Tuesday, September 26th. ValuEngine lowered Cellectis from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub lowered Cellectis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 16th. Finally, SunTrust Banks reissued a “hold” rating and set a $20.00 price objective on shares of Cellectis in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $39.29.

TRADEMARK VIOLATION WARNING: “Cellectis (CLLS) Earning Somewhat Favorable Press Coverage, Study Finds” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/01/21/cellectis-clls-earning-somewhat-favorable-press-coverage-study-finds.html.

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Insider Buying and Selling by Quarter for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply